NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from M ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized m ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman o ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman ...

Core Viewpoint - The ATTENTION-AD trial data indicates that oral blarcamesine has a disease-modifying effect on chronic Alzheimer's disease, emphasizing the importance of early and continuous long-term treatment for patients [1][3][10]. Efficacy Data - Over three years of continuous treatment with blarcamesine showed significant clinical benefits for early Alzheimer's disease patients, as measured by clinical endpoints ADAS-Cog13 and ADCS-ADL [1][3]. - The delayed-start analysis revealed a significant difference in cognitive function between early and late treatment groups, with a LS mean difference of -3.83 for ADAS-Cog13 (P = 0.0165) and +4.30 for ADCS-ADL (P = 0.0206) at Week 192 [6][7]. - Continuous treatment without interruption resulted in improved cognitive and functional outcomes, with LS mean differences of -4.20 for ADAS-Cog13 (P = 0.0083) and +5.75 for ADCS-ADL (P = 0.0015) at Week 192 [9][10]. Safety Data - Blarcamesine exhibited a favorable safety profile, with most adverse events being mild to moderate and manageable through adjusted titration schedules [11][12]. - No severe or life-threatening adverse events were reported, and there were no treatment-related deaths [2][11]. - The frequency of dizziness, the most common treatment-emergent adverse event, decreased significantly from 25.2% in the previous trial to 9.6% in the ATTENTION-AD trial [12]. Compassionate Use - Currently, 74 participants are receiving blarcamesine through a Compassionate Use Program, with some individuals on treatment for over 9 years without severe adverse events [14]. Industry Implications - The results from the ATTENTION-AD trial suggest a potential shift towards more effective and patient-friendly Alzheimer's treatments, addressing disparities in care within global healthcare systems [4][15]. - The findings support the notion that early diagnosis and treatment can lead to greater clinical benefits for Alzheimer's patients, which may enhance the quality of life for patients and their families [15].

Core Insights - The ATTENTION-AD trial data presented at the AD/PDTM 2025 Conference indicates that oral blarcamesine has a disease-modifying effect and emphasizes the importance of early and continuous long-term treatment for chronic Alzheimer's disease [1][3][10] Efficacy Data - Continuous treatment with blarcamesine for up to four years showed a favorable safety profile with no treatment-related deaths and no serious neuroimaging adverse events [2][11] - The delayed-start analysis demonstrated a significant difference in cognitive function between early and late treatment groups, with an LS mean difference of -3.83 for ADAS-Cog13 (P = 0.0165) and +4.30 for ADCS-ADL (P = 0.0206) at Week 192 [6][7] - Patients who started treatment earlier exhibited greater stability in cognitive function compared to those who delayed treatment by approximately one year [6][10] - The analysis confirmed that continuous treatment without interruption led to improved outcomes in both cognition and function, with LS mean differences of -4.20 (P = 0.0083) for ADAS-Cog13 and +5.75 (P = 0.0015) for ADCS-ADL at Week 192 [9][10] Safety Data - Blarcamesine was associated with mostly mild to moderate adverse events, primarily during the initial titration phase, and no severe or life-threatening adverse events were reported [11][12] - The frequency of dizziness, the most common treatment-emergent adverse event, decreased significantly from 25.2% in the previous trial to 9.6% in the ATTENTION-AD trial, indicating better management of side effects [12] Compassionate Use - Currently, 74 participants are receiving blarcamesine through a Compassionate Use Program, with some individuals having been on the treatment for over nine years without severe adverse events [14] Industry Implications - The results suggest a potential shift towards more effective and patient-friendly Alzheimer's treatments, addressing disparities in care within global healthcare systems [4][15] - The findings support the notion that early diagnosis and treatment can lead to greater clinical benefits for patients with Alzheimer's disease [4][15]

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference, April 7 – 10, 2025. C ...

Core Insights - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease and Parkinson's disease [1][3] - The company will present at the 45th Annual TD Cowen Health Care Conference on March 3, 2025, with CEO Christopher U Missling scheduled to speak [1][2] Company Overview - Anavex Life Sciences Corp. is publicly traded on Nasdaq under the ticker AVXL and is dedicated to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [3] - The lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3] - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease [3] - The company is also developing ANAVEX3-71, which targets SIGMAR1 and M1 muscarinic receptors, showing promise in addressing cognitive deficits and other hallmarks of Alzheimer's disease in preclinical trials [3]

Group 1 - Anavex Life Sciences Corp. (NASDAQ: AVXL) experienced a stock price increase of over 50% between late December and early January, despite a generally lackluster performance in the previous year [1] - The stock's performance has drawn attention, indicating potential investor interest and market activity surrounding the company [1] Group 2 - The Total Pharma Tracker offers tools for DIY investors, including a software that provides extensive curated research material for any ticker [1] - For investors seeking hands-on support, in-house experts assist in identifying the best investable stocks along with buy/sell strategies and alerts [2]

Group 1 - Anavex Life Sciences Corp. (NASDAQ: AVXL) published data from its phase 2b/3 study on blarcamesine for treating early Alzheimer's Disease in The Journal of Prevention of Alzheimer's Disease [2] - The study results are significant for the pharmaceutical industry, particularly in the Alzheimer's treatment sector, as they may influence future research and investment strategies [2] Group 2 - The Biotech Analysis Central service offers extensive resources for investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] - The service aims to assist healthcare investors in making informed decisions through deep analysis and live chat features [2]